Sunshine Guojian Reports 95% Profit Surge on R&D Expansion

The company’s total operating revenue climbed 34.84% to RMB 866 million, fueled by a robust commercialization platform that spans nearly 4,800 medical institutions. To sustain this momentum, Sunshine Guojian increased its R&D spending by 32.41% to RMB 245 million, prioritizing a pipeline that balances near-term commercial products with long-term innovative targets. Shareholders are set to receive a cash dividend of RMB 0.42 per 10 shares, reflecting the firm's improved cash flow.

Product development remains the primary driver. In 2026, the company secured NMPA approvals for Yisaituo—a treatment for moderate-to-severe plaque psoriasis—and Yisaina, an anti-IL-1β monoclonal antibody for gouty arthritis. Furthermore, clinical progress has accelerated for the SSGJ-707 program, a global collaboration with Pfizer currently undergoing multicenter trials for solid tumors. With additional candidates in Phase III trials, including treatments for atopic dermatitis and asthma, the company is shifting its focus toward a diverse portfolio that now encompasses bispecific and trispecific antibodies.